Cartalax vs Sigumir

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging. Published preclinical studies of structurally related Khavinson peptides show regulation of aging-associated genes and epigenetic markers in mesenchymal stem cell models. Human clinical evidence specific to cartalax is limited; existing research is predominantly preclinical and based on related peptides within the same class. Cartalax benefits investigated in preclinical research include support for chondrocyte proliferation, extracellular matrix synthesis, and cartilage tissue homeostasis — areas relevant to age-related joint degeneration, osteoarthritis research, and connective tissue maintenance. As a bioregulator peptide, cartalax is proposed to work by modulating gene expression in cartilage-specific cells rather than providing direct structural repair, distinguishing it mechanistically from direct injections of growth factors or PRP. Research interest also extends to combined bioregulator protocols pairing cartalax with other Khavinson-class peptides targeting musculoskeletal and connective tissue health, including protocols used alongside cortagen for vascular-connective tissue support. Cartalax dosage: No human clinical trial has established a reference dose for cartalax. Preclinical research protocols in the Khavinson bioregulator literature have examined peptide bioregulators at doses in the microgram-to-low-milligram range via subcutaneous injection, typically administered in defined cycles. Oral bioregulator formulations of related Khavinson peptides have also been studied. Cartalax is a research compound with no approved human dosing guidelines.

Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

Sigumir is a Khavinson-class short bioregulator peptide investigated for joint, cartilage, and connective tissue support. Like other ultrashort peptides in this research category, sigumir is proposed to reach musculoskeletal target tissues via amino acid transporter mechanisms and modulate gene expression in aging musculoskeletal cells. Published research on related Khavinson bioregulator peptides documents transport feasibility across biological membranes and broad gene expression regulatory effects in preclinical aging models. Human clinical data specific to sigumir is sparse; evidence is based on class-level mechanistic and preclinical research rather than direct sigumir-specific trials. Sigumir dosing and research context Sigumir is typically formulated as an oral capsule or sublingual peptide bioregulator in the Khavinson research tradition, with protocols in the preclinical literature referencing cycles of 10–20 days at low doses (in the range of 5–10mg per cycle, divided daily), followed by rest intervals. This intermittent dosing pattern is characteristic of the Khavinson bioregulator peptide class — the proposed mechanism involves gene expression modulation in target tissue cells rather than continuous receptor occupancy, which is argued to support pulse-dosing protocols. Sigumir's proposed target tissue is articular cartilage and connective tissue, distinguishing it from other Khavinson peptides that target specific organ systems (e.g., Testagen for testicular tissue, Thymalin for thymic tissue). Available through specialty peptide vendors and some Eastern European pharmacy channels as a research or supplement product; not available as a prescription medication in Western markets and not FDA-reviewed.